Figure 7
Influence of human plasma on ADCC activity of fucosylated anti-CD20. (a) B-cell depletion activity of non-fucosylated and fucosylated anti-CD20 was analyzed using purified PBMC with (closed circle) or without (open circle) auto-plasma (donors 6 and 7). Cytotoxicity (%) after 4-h treatment was calculated as described in Materials and Methods. (b) B-cell depletion activity of fucosylated anti-CD20 was analyzed using purified PBMC from donor 8 with (gray column) or without (black column) allo-serum from 12 healthy adult individuals. Cytotoxicity (%) after 4-h treatment was calculated as described in Materials and Methods, and is indicated by mean values ± SD of triplicates. Individual differences in endogenous IgG1 profiles of the allo-serum, endogenous IgG1 concentration (c) (indicated by mean values ± SD of triplicates) and relative amounts of non-fucosylated IgG1 Fc oligosaccharide (d) were also analyzed. The fucosylated and non-fucosylated anti-CD20 IgG1s (Fig. 2) with known fucosylation level and antibody concentration (2 mg/mL and 10 mg/mL) were used as standard antibodies for experiments (c) and (d).